BAT 8010
Alternative Names: BAT-8010Latest Information Update: 18 Jun 2024
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 08 May 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable) in China (Parenteral) ((NCT06376136) )
- 24 Apr 2024 Bio-Thera Solutions plans a phase I/II trial in Solid tumours (Metastatic disease, Late-stage disease, Combination therapy, Inoperable/Unresectable) (IV) (NCT06376136)
- 08 Mar 2023 Bio-Thera Solutions plans a combination trial with BAT 1006